Ligand Pharmaceuticals Incorporated LGND
301.52
2.48
0.83%
as of 25 Sep
- Market cap
- $6.1B
- P/E
- 30.1×
Follow LGND
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 21.96% | 17.13% | 13.47% | 5.42% |
+8 more TTM periods Free account |
|
| 12.58% | 12.60% | 9.95% | 4.00% | ||
ROIC |
8.19% | 9.06% | 3.62% | 1.52% | |
Return on Tangible Assets |
13.98% | 18.62% | 15.66% | 6.68% | |
Average Days of Receivables |
87.84 | 72.87 | 83.12 | 84.40 | |
Free Cash Flow per Share |
7.15 | 6.77 | 3.15 | 0.62 | |
Free Cash Flow |
143.37 | 134.59 | 60.91 | 12.13 | |
Capital Expenditures |
11.65 | 11.09 | 11.56 | (19.79) | |
Piotroski F-Score |
5.00 | 6.00 | 6.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
3.80% | 5.52% | 2.22% | 1.54% | |
Accounts Receivable Turnover |
4.75 | 5.62 | 5.18 | 5.01 | |
Accounts Payable Turnover |
1.48 | 2.44 | 3.44 | 3.44 | |
Inventory Turnover |
1.03 | 0.93 | 1.25 | 1.01 | |
Average Days of Payables |
258.50 | 148.10 | 81.23 | 93.29 | |
Days of Inventory on Hand |
282.08 | 373.24 | 228.95 | 301.76 | |
Tax Rate |
(0.17) | (0.17) | (0.22) | (0.23) | |
Research and Development Expense of Revenue |
14.23% | 12.11% | 30.28% | 32.68% | |
Selling, General and Administrative Expense of Revenue |
35.60% | 34.42% | 34.48% | 37.03% | |
Share Based Compensation of Revenue |
18.33% | 18.07% | 17.48% | 15.96% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.67 | 0.80 | 0.40 | 0.66 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 9.09 | |
Capex/Depreciation |
0.40 | 0.38 | 0.38 | (0.63) | |
Revenue per Share |
14.48 | 13.80 | 13.86 | 12.83 | |
Operating CF per Share |
6.57 | 6.21 | 2.55 | 1.63 | |
Capex per Share |
0.58 | 0.56 | 0.60 | (1.01) | |
Capex to Sales |
(0.04) | (0.04) | (0.04) | 0.08 | |
Net Profit Margin |
67.88% | 55.95% | 46.42% | 19.34% |
Columns are period end dates